Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

In the recent news, Viking Therapeutics, on Jan. 8, announced the initiation of Phase 2 VENTURE-oral dosing trial of VK2735 tablet formulation in patients with obesity. “This group is just not ...

Dana Incorporated (NYSE:DAN) rallied on Friday after providing fresh guidance and a business update. For the full year, the auto supplier said it expects to report sales of approximately $10.3 ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) today announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the ...

BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of $125.00. Justin Zelin has given his Buy rating due to a ...

Now let's talk about the new kid in town. Viking focuses on GIP/GLP-1 receptor agonists and has a candidate, VK2735, in late-stage clinical trials. As an injectable (like the Novo Nordisk and ...